Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant

Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and clinical transplantation 2021-03, Vol.19 (3), p.269-272
Main Authors: Giordano, Chris, Johnson, Chris, Lawson, Janice, Rajasekhar, Anita, Thomas, Elizabeth
Format: Article
Language:English
Subjects:
Tıp
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73
cites cdi_FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73
container_end_page 272
container_issue 3
container_start_page 269
container_title Experimental and clinical transplantation
container_volume 19
creator Giordano, Chris
Johnson, Chris
Lawson, Janice
Rajasekhar, Anita
Thomas, Elizabeth
description Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this case report, we discuss the first reported use of recombinant fibrinogen to treat such a patient and the decision-making process considered to balance the thrombotic and hemorrhagic risks.
doi_str_mv 10.6002/ect.2017.0316
format article
fullrecord <record><control><sourceid>idealonline_cross</sourceid><recordid>TN_cdi_idealonline_journals_IDEAL_131594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IDEAL_131594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73</originalsourceid><addsrcrecordid>eNotkM9LwzAYhoMoOOaO3nv00prfSY9lmzooKDrP4UuWjkiXjqQT_O_tnKePl-_hfeFB6J7gSmJMH70bK4qJqjAj8grNKOGy1JyqazQjDPMSayFu0SLnYDHnSlEu9Qy1ze4QYsijTyHui_cAH9vmreiGVCyHuPcxjNAXTRfs9B-m7A8BitXpj27Dt0_FNkHMxx7ieIduOuizX_zfOfp8Wm-XL2X7-rxZNm3pGJVjCZZQoM4Rz6iwFHANQCVoDkwrZe0O65oA5p7zWghHOSZSaKdJV9eWesXm6OHSG3Ye-iH2IXrzNZxSnFbNZrVuWkMYETWf0PKCujTknHxnjikcIP0Ygs1ZnJnEmbM4cxbHfgEB_GBE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant</title><source>Freely Accessible Science Journals at publisher websites</source><creator>Giordano, Chris ; Johnson, Chris ; Lawson, Janice ; Rajasekhar, Anita ; Thomas, Elizabeth</creator><contributor>Haberal,Mehmet</contributor><creatorcontrib>Giordano, Chris ; Johnson, Chris ; Lawson, Janice ; Rajasekhar, Anita ; Thomas, Elizabeth ; Haberal,Mehmet</creatorcontrib><description>Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this case report, we discuss the first reported use of recombinant fibrinogen to treat such a patient and the decision-making process considered to balance the thrombotic and hemorrhagic risks.</description><identifier>ISSN: 1304-0855</identifier><identifier>EISSN: 2146-8427</identifier><identifier>DOI: 10.6002/ect.2017.0316</identifier><language>eng</language><publisher>Başkent Üniversitesi</publisher><subject>Tıp</subject><ispartof>Experimental and clinical transplantation, 2021-03, Vol.19 (3), p.269-272</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73</citedby><cites>FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><contributor>Haberal,Mehmet</contributor><creatorcontrib>Giordano, Chris</creatorcontrib><creatorcontrib>Johnson, Chris</creatorcontrib><creatorcontrib>Lawson, Janice</creatorcontrib><creatorcontrib>Rajasekhar, Anita</creatorcontrib><creatorcontrib>Thomas, Elizabeth</creatorcontrib><title>Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant</title><title>Experimental and clinical transplantation</title><description>Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this case report, we discuss the first reported use of recombinant fibrinogen to treat such a patient and the decision-making process considered to balance the thrombotic and hemorrhagic risks.</description><subject>Tıp</subject><issn>1304-0855</issn><issn>2146-8427</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNotkM9LwzAYhoMoOOaO3nv00prfSY9lmzooKDrP4UuWjkiXjqQT_O_tnKePl-_hfeFB6J7gSmJMH70bK4qJqjAj8grNKOGy1JyqazQjDPMSayFu0SLnYDHnSlEu9Qy1ze4QYsijTyHui_cAH9vmreiGVCyHuPcxjNAXTRfs9B-m7A8BitXpj27Dt0_FNkHMxx7ieIduOuizX_zfOfp8Wm-XL2X7-rxZNm3pGJVjCZZQoM4Rz6iwFHANQCVoDkwrZe0O65oA5p7zWghHOSZSaKdJV9eWesXm6OHSG3Ye-iH2IXrzNZxSnFbNZrVuWkMYETWf0PKCujTknHxnjikcIP0Ygs1ZnJnEmbM4cxbHfgEB_GBE</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Giordano, Chris</creator><creator>Johnson, Chris</creator><creator>Lawson, Janice</creator><creator>Rajasekhar, Anita</creator><creator>Thomas, Elizabeth</creator><general>Başkent Üniversitesi</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope></search><sort><creationdate>20210301</creationdate><title>Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant</title><author>Giordano, Chris ; Johnson, Chris ; Lawson, Janice ; Rajasekhar, Anita ; Thomas, Elizabeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Tıp</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giordano, Chris</creatorcontrib><creatorcontrib>Johnson, Chris</creatorcontrib><creatorcontrib>Lawson, Janice</creatorcontrib><creatorcontrib>Rajasekhar, Anita</creatorcontrib><creatorcontrib>Thomas, Elizabeth</creatorcontrib><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><jtitle>Experimental and clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giordano, Chris</au><au>Johnson, Chris</au><au>Lawson, Janice</au><au>Rajasekhar, Anita</au><au>Thomas, Elizabeth</au><au>Haberal,Mehmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant</atitle><jtitle>Experimental and clinical transplantation</jtitle><date>2021-03-01</date><risdate>2021</risdate><volume>19</volume><issue>3</issue><spage>269</spage><epage>272</epage><pages>269-272</pages><issn>1304-0855</issn><eissn>2146-8427</eissn><abstract>Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this case report, we discuss the first reported use of recombinant fibrinogen to treat such a patient and the decision-making process considered to balance the thrombotic and hemorrhagic risks.</abstract><pub>Başkent Üniversitesi</pub><doi>10.6002/ect.2017.0316</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1304-0855
ispartof Experimental and clinical transplantation, 2021-03, Vol.19 (3), p.269-272
issn 1304-0855
2146-8427
language eng
recordid cdi_idealonline_journals_IDEAL_131594
source Freely Accessible Science Journals at publisher websites
subjects Tıp
title Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A20%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-idealonline_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Administering%20RiaSTAP%20for%20Congenital%20Afibrinogenemia%20During%20Liver%20Transplant&rft.jtitle=Experimental%20and%20clinical%20transplantation&rft.au=Giordano,%20Chris&rft.date=2021-03-01&rft.volume=19&rft.issue=3&rft.spage=269&rft.epage=272&rft.pages=269-272&rft.issn=1304-0855&rft.eissn=2146-8427&rft_id=info:doi/10.6002/ect.2017.0316&rft_dat=%3Cidealonline_cross%3EIDEAL_131594%3C/idealonline_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-ab12a2cc1e325b2a09aa26a84a3877bbd0891a04e44955c2401658c81f99b2e73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true